专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2014051510A Fusion peptide therapeutic compositions 有权
标题翻译： FUSION PEPTIDE治疗组合物
公开(公告)号：JP2014051510A
公开(公告)日：2014-03-20
申请号：JP2013217181
申请日：2013-10-18
申请人： Phasebio Pharmaceuticals Inc , フェーズバイオファーマシューティカルズ,インコーポレイテッド
发明人： CHILKOTI ASHUTOSH
IPC分类号： A61K38/00 , A61K38/21 , A61K38/22 , A61K38/27 , A61K38/28 , A61K38/45 , A61K38/46 , A61K47/48 , A61K48/00 , C07K14/78 , C07K19/00 , C12N15/09
CPC分类号： A61K38/26 , A61K38/00 , A61K38/162 , A61K38/1709 , A61K38/177 , A61K38/1796 , A61K38/212 , A61K38/28 , A61K38/39 , A61K38/443 , A61K38/4873 , A61K47/6435 , C07K14/78 , C07K2319/01
摘要： PROBLEM TO BE SOLVED: To provide therapeutic compositions capable of improving the enhanced efficacy of a peptide active therapeutic agent to be achieved, in relation to the peptide active therapeutic agent alone.SOLUTION: Therapeutic compositions contain fusion proteins (FPs) including elastin-like peptides (ELPs) and peptide active therapeutic agents. Enhanced efficacy of the peptide active therapeutic agent in the therapeutic composition may include improved solubility, bioavailability, bio-unavailability, half-life, etc., as compared to corresponding compositions containing the same peptide active therapeutic agent without associated ELPs.
摘要翻译：要解决的问题：提供相对于单独的肽活性治疗剂，能够提高能够实现肽活性治疗剂增强功效的治疗组合物。解决方案：治疗组合物含有融合蛋白（FP），包括弹性蛋白样肽（ELP）和肽活性治疗剂。与含有相同肽活性治疗剂而不伴有ELP的相应组合物相比，肽活性治疗剂在治疗组合物中的增强功效可包括提高的溶解度，生物利用度，生物不可用性，半衰期等。

2. 发明申请

WO2015172046A1 METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS 审中-公开
标题翻译：用于治疗CYSTIC FIBROSIS的方法和组合物
公开(公告)号：WO2015172046A1
公开(公告)日：2015-11-12
申请号：PCT/US2015/029926
申请日：2015-05-08
申请人： PHASEBIO PHARMACEUTICALS, INC.
发明人： ARNOLD, Susan , BALLANCE, David James
IPC分类号： A61K38/26
CPC分类号： A61K38/2278 , A61K31/404 , A61K31/443 , A61K31/47 , A61K38/39 , A61K45/06 , A61K2300/00
摘要： The present disclosure provides a method of treating diseases or disorders associated with CFTR protein dysfunction, including Cystic Fibrosis, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents. These agents include one or more elastin-like peptides and can be administered at a low-dose.
摘要翻译：本公开提供了通过施用稳定的持久的血管活性肠肽治疗剂来治疗与CFTR蛋白功能障碍相关的疾病或病症的方法，包括囊性纤维化。这些试剂包括一种或多种弹性蛋白样肽，并且可以以低剂量施用。

3. 发明申请

WO2013028989A1 FORMULATIONS OF ACTIVE AGENTS FOR SUSTAINED RELEASE 审中-公开
标题翻译：活性剂用于持续释放的配方
公开(公告)号：WO2013028989A1
公开(公告)日：2013-02-28
申请号：PCT/US2012/052304
申请日：2012-08-24
申请人： PHASEBIO PHARMACEUTICALS, INC. , ARNOLD, Susan , PRIOR, Christopher
发明人： ARNOLD, Susan , PRIOR, Christopher
IPC分类号： A61M31/00
CPC分类号： A61K38/17 , A61K9/0002 , A61K9/0019 , A61K9/0024 , A61K38/2278 , A61K38/26 , A61K38/39 , A61K47/42
摘要： The present invention provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs. A sustained release pharmaceutical formulation comprises a therapeutic agent for systemic administration, where the therapeutic agent comprises an active agent and an amino acid sequence capable of forming a reversible matrix at the body temperature of a subject.
摘要翻译：本发明提供用于持续释放的药物制剂，以及用持续释放和长半衰期制剂组合递送治疗方案的方法。本发明提供肽和小分子药物的改善的药代动力学。持续释放的药物制剂包含用于全身给药的治疗剂，其中治疗剂包含活性剂和能够在个体体温形成可逆基质的氨基酸序列。

4. 发明申请

WO2010014689A1 PHARMACEUTICAL FORMULATIONS COMPRISING ELASTIN-LIKE PROTEINS 审中-公开
标题翻译：包含类似蛋白样蛋白的药物制剂
公开(公告)号：WO2010014689A1
公开(公告)日：2010-02-04
申请号：PCT/US2009/052080
申请日：2009-07-29
申请人： PHASEBIO PHARMACEUTICALS, INC. , DAGHER, Sue , PRIOR, Chris , SADEGHI, Homayoun
发明人： DAGHER, Sue , PRIOR, Chris , SADEGHI, Homayoun
IPC分类号： A01N25/00 , A61K47/00
CPC分类号： A61K38/39 , A61K9/0019 , A61K9/19
摘要： The present invention provides stable pharmaceutical compositions or formulations, including solution and non-solution phase formulations, and methods of preparing the same. The formulations of the invention may improve the stability and/or solubility of various pharmaceutically-active ingredients, including biological molecules and small drug compounds, and may be tailored to a variety of storage conditions. The formulations of the invention may provide an alternative to lyophilization, or may be employed together with lyophilization or other methods of stabilization. Generally, the compositions comprise a pharmaceutically active ingredient, such as a biological molecule or small drug compound, and a pharmaceutically acceptable carrier. The carrier comprises an Elastin-Like Peptide (ELP) in an amount and form (e.g., soluble or insoluble form) effective for stabilizing the pharmaceutically active ingredient.
摘要翻译：本发明提供稳定的药物组合物或制剂，包括溶液和非溶液相制剂，及其制备方法。本发明的制剂可以改善各种药物活性成分（包括生物分子和小药物化合物）的稳定性和/或溶解性，并且可以针对各种储存条件进行调整。本发明的制剂可以提供冷冻干燥的替代方案，或者可以与冷冻干燥或其它稳定方法一起使用。通常，组合物包含药物活性成分，例如生物分子或小药物化合物和药学上可接受的载体。载体包含有效稳定药物活性成分的量和形式（例如可溶性或不溶性形式）的弹性蛋白样肽（ELP）。

5. 发明申请

WO2014113434A1 THERAPEUTIC AGENTS, COMPOSITIONS, AND METHODS FOR GLYCEMIC CONTROL 审中-公开
标题翻译：治疗药物，组合物和用于糖化控制的方法
公开(公告)号：WO2014113434A1
公开(公告)日：2014-07-24
申请号：PCT/US2014/011620
申请日：2014-01-15
申请人： PHASEBIO PHARMACEUTICALS, INC.
发明人： JOWETT, James , WOODS, Christopher , ARNOLD, Susan
IPC分类号： A61K38/28
CPC分类号： C07K14/62 , A61K38/26 , A61K38/28 , C07K2319/00 , A61K2300/00
摘要： The present invention relates in part to insulin proteins and pharmaceutical compositions having therapeutic advantages. The effectiveness of peptide and small molecule drugs is often limited by the half-life of such drugs in the circulation, as well as difficulties in obtaining substantially constant plasma levels. For example, the incretin GLP-I must be administered at relatively high doses to counter its short half-life in the circulation, and these high doses arc associated with nausea, among other things. Murphy and Bloom, Nonpeptide glucagon-like peptide 1 receptor agonists: A magic bullet for diabetes?
摘要翻译：本发明部分涉及具有治疗优点的胰岛素蛋白和药物组合物。肽和小分子药物的有效性通常受到这些药物在循环中的半衰期以及难以获得基本上恒定的血浆水平的限制。例如，肠降血糖素GLP-1必须以相对高的剂量施用以抵消其在循环中的短的半衰期，并且这些高剂量与恶心相关。墨菲和布鲁姆，非肽胰高血糖素样肽1受体激动剂：糖尿病的魔法子弹？

6. 发明申请

WO2014081849A1 FORMULATIONS OF ACTIVE AGENTS FOR SUSTAINED RELEASE 审中-公开
标题翻译：活性剂用于持续释放的配方
公开(公告)号：WO2014081849A1
公开(公告)日：2014-05-30
申请号：PCT/US2013/071038
申请日：2013-11-20
申请人： PHASEBIO PHARMACEUTICALS, INC. , ARNOLD, Susan , PRIOR, Christopher , GEORGOPOULOS, Lynne
发明人： ARNOLD, Susan , PRIOR, Christopher , GEORGOPOULOS, Lynne
IPC分类号： A61K38/00 , A61K9/52 , A61K9/22
CPC分类号： A61K38/2278 , A61K9/0019 , A61K38/00 , A61K38/16 , A61K38/26 , A61K38/28 , A61K45/06 , A61K47/02 , A61K47/183 , A61K47/42 , A61K47/6435
摘要： The present invention provides pharmaceutical formulations for sustained release when administered at cold temperatures, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs.
摘要翻译：本发明提供了在冷温度下给药时用于持续释放的药物制剂，以及用持续释放和长半衰期制剂组合递送治疗方案的方法。本发明提供肽和小分子药物的改善的药代动力学。

7. 发明申请

WO2010124180A1 PHENYLALANINE HYDROXYLASE FUSION PROTEIN AND METHODS FOR TREATING PHENYLKETONURIA 审中-公开
标题翻译：苯丙氨酸羟化酶融合蛋白及其治疗方法
公开(公告)号：WO2010124180A1
公开(公告)日：2010-10-28
申请号：PCT/US2010/032194
申请日：2010-04-23
申请人： PHASEBIO PHARMACEUTICALS, INC. , TURNER, Andrew , SADEGHI, Homayoun
发明人： TURNER, Andrew , SADEGHI, Homayoun
IPC分类号： A61K38/00 , C07K16/00
CPC分类号： C12N9/0071 , A61K38/00 , C07K2319/00
摘要： The present invention provides Phenylalanine Hydroxylase (PAH) fusion proteins and pharmaceutical compositions comprising the same, as well as encoding polynucleotides and vectors, and methods for treating hyperphenylalaninemia, including PKU, by enzyme replacement therapy. The fusion proteins have phenylalanine hydroxylase activity when administered, and have an increased half-life or persistence in circulation, as compared to unfused counterparts. The PAH fusion proteins are suitable for enzyme replacement therapy in PKU patients by converting phenylalanine in the circulation to tyrosine, thereby controlling phenylalanine levels.
摘要翻译：本发明提供苯丙氨酸羟化酶（PAH）融合蛋白和包含其的药物组合物，以及编码多核苷酸和载体，以及通过酶替代疗法治疗高苯丙氨酸血症（包括PKU）的方法。融合蛋白在施用时具有苯丙氨酸羟化酶活性，并且与未融合的对应物相比具有增加的半衰期或循环持久性。通过将循环中的苯丙氨酸转化为酪氨酸，PAH融合蛋白适用于PKU患者的酶替代治疗，从而控制苯丙氨酸水平。

8. 发明申请

WO2022240754A2 PHARMACOKINETIC & PHARMACODYNAMIC MODEL FOR DETERMINING EFFECTIVE DOSE OF ANTI-TICAGRELOR ANTIBODY 审中-公开
公开(公告)号：WO2022240754A2
公开(公告)日：2022-11-17
申请号：PCT/US2022/028343
申请日：2022-05-09
申请人： PHASEBIO PHARMACEUTICALS, INC.
发明人： LEE, John
IPC分类号： A61K39/395 , A61P39/02 , C07D487/04 , C07K16/44 , A61K31/519 , A61P7/02 , A61P7/04 , A61K38/00 , A61K39/00 , C07K16/00
摘要： The present disclosure provides a model to mathematically explore and predict the pharmacokinetic and pharmacodynamic relationships between of PB2452, its interaction with ticagrelor and the active metabolite, and the ability of PB2452 to reverse the antiplatelet effects of ticagrelor. This model may be used to determine dosing regiments of PB2452 for a particular patient population.

9. 发明申请

WO2021226244A1 VASOACTIVE INTESTINAL PEPTIDE FUSION PROTEINS FOR THE TREATMENT OF COVID-19 审中-公开
公开(公告)号：WO2021226244A1
公开(公告)日：2021-11-11
申请号：PCT/US2021/030901
申请日：2021-05-05
申请人： PHASEBIO PHARMACEUTICALS, INC.
发明人： LEE, John , SUMITA, Paul
IPC分类号： A61K31/404 , A61K31/443 , A61K31/47 , A61K38/22 , A61K38/26 , A61K38/39
摘要： The present disclosure provides methods of treating inflammatory lung conditions such as COVID-19 with a fusion protein comprising a vasoactive intestinal peptide (VIP) and an elastin-like peptide.

10. 发明申请

WO2013003449A2 METHODS OF TREATMENT WITH GLP-1 RECEPTOR AGONISTS 审中-公开
标题翻译：用GLP-1受体激动剂治疗的方法
公开(公告)号：WO2013003449A2
公开(公告)日：2013-01-03
申请号：PCT/US2012/044383
申请日：2012-06-27
申请人： PHASEBIO PHARMACEUTICALS, INC. , GEORGOPOULOS, Lynne M. , ARNOLD, Susan
发明人： GEORGOPOULOS, Lynne M. , ARNOLD, Susan
IPC分类号： A61K38/26
CPC分类号： C07K14/605 , A61K9/0019 , A61K38/26 , A61K38/39 , C07K14/78 , C07K2319/00
摘要： The invention provides methods for treating diabetes or obesity, as well as methods for inducing weight loss, preventing weight gain, or controlling weight in a patient in need thereof. The methods comprise administering to the patient at least one effective dose of a GLP-1 receptor agonist, or a regimen of GLP-1 receptor agonist comprising a plurality of substantially evenly spaced doses. The effective dose or regimen does not induce substantial nausea or appetite suppression in the patient.
摘要翻译：本发明提供了治疗糖尿病或肥胖症的方法，以及用于诱导有此需要的患者的体重减轻，预防体重增加或控制体重的方法。该方法包括向患者施用至少一种有效剂量的GLP-1受体激动剂或包含多个基本上均匀间隔的剂量的GLP-1受体激动剂方案。有效剂量或治疗方案不会导致患者大量恶心或抑制食欲。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式